Hydroxyurea Treatment for Sickle Cell Disease
High fetal hemoglobin (HbF) levels inhibit the polymerization of sickle hemoglobin (HbS) and reduce the complications of sickle cell disease. Pharmacologic agents that can reverse the switch from γ- to β-chain synthesis — γ-globin chains characterize HbF, and sickle β-globin chains are present in Hb...
Saved in:
Main Author: | Martin H. Steinberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2002-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/tsw.2002.295 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?
by: Mohammed Ali Al Sabbah, et al.
Published: (2023-07-01) -
Nutritional Evaluation of Pediatric Patients with Sickle Cell Disease Treated with Hydroxyurea
by: Belkis Lázara Rodríguez Jorge, et al.
Published: (2021-03-01) -
The modern use of hydroxyurea for children with sickle cell anemia
by: Charles T. Quinn, et al.
Published: (2025-01-01) -
Impact of hydroxyurea on clinical and biological parameters of sickle cell anemia in children in Abidjan
by: MIREILLE YAYO- AYE, et al.
Published: (2024-02-01) -
Sickle Cell Anemia Treatment With Hydroxyurea in Low-Resource Settings: Challenges and Opportunities for Global North-South Collaboration
by: Teresa S. Latham
Published: (2025-01-01)